The Effect of Potentially Hepatotoxic Medicinal Products on Alanine Transaminase Levels in COVID-19 Patients: A Case–Control Study

The Effect of Potentially Hepatotoxic Medicinal Products on Alanine Transaminase Levels in COVID-19 Patients: A Case–Control Study

INTRODUCTION. Elevated liver enzyme levels are common in patients with COVID-19. Personalised prescribing to reduce the risk of hepatotoxicity requires studying the role of pharmacotherapy in the development of liver dysfunction in COVID-19 patients.AIM. This study aimed to identify the presence and...

Full description

Saved in:
Bibliographic Details
Main Authors: V. I. Petrov, A. Yu. Ryazanova, N. S. Tokareva
Format: Article
Language:Russian
Published: Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» 2025-06-01
Series:Безопасность и риск фармакотерапии
Subjects:
drug-induced liver injury
rucam scale
covid-19
matched case–control study, alanine transaminase
favipiravir
remdesivir
tocilizumab
olokizumab
levilimab
omeprazole
Online Access:https://www.risksafety.ru/jour/article/view/458
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.risksafety.ru/jour/article/view/458

Similar Items